In addition, head and neck squamous cell carcinoma (HNSCC) and the human papillomavirus (HPV) therapy with HER receptors, anti-EGFR therapies have shown that (46) afatinib monotherapy or afatinib combined with carboplatin can increase the sensitivity of cetuximab‐resistant cells. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.